CRA provided expert reports and trial testimony in trade secret litigation concerning an early-stage oncology product candidate. Plaintiff claimed that the alleged misappropriation led to accelerated development of a competing potential treatment. CRA quantified unjust enrichment using a methodology that measured the value associated with accelerated development, recognizing advantages associated with early versus late entry into the marketplace.
IP Literature Watch: March 2024
In this month’s IP Literature Watch we include an article analyzing four case studies of controversy over license design in open-source software and hardware...